Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth
We are Abingworth, a transatlantic bioscience investment firm with a deep understanding of both the science and markets we invest in.
Explore our PortfolioFor over 30 years, Abingworth has been working alongside entrepreneurs to develop their ideas into products that have a dramatic impact on health. With a broad transatlantic approach to backing innovation, we invest in drugs, devices and diagnostics from seed-stage start-ups to publicly traded companies.
From decades of experience, we understand that one of the keys to building a great company is true partnership between entrepreneurs and their investors.
Helping clever and committed people turn scientific breakthroughs into significant new advances in healthcare? We can’t imagine many more rewarding endeavours.
By harnessing advances in life sciences, we have built a succession of companies and helped to create one of the world’s most vibrant and important industries.
Our longstanding commitment to partnering with entrepreneurs is evident throughout our portfolio. From T-cells to inflammasomes, gene editing to gene therapy, conjugate vaccines to novel antibiotics, we invest in a broad range of cutting-edge approaches. We also invest in small later-stage biotech companies, including some that are publicly traded, and in clinical co-development programmes with major pharmaceutical firms.
Collectively, the Abingworth team has many decades of experience in almost every aspect of starting and growing a biotech company. Whatever the challenge - creating your company, building your team, developing your strategy, advancing your programmes, negotiating with big pharma - our partners and advisors will be there to help you.
One of the joys of working with small companies is seeing the speed that they make progress and we are always proud to share their achievements.